<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517955</url>
  </required_header>
  <id_info>
    <org_study_id>088891/2019</org_study_id>
    <nct_id>NCT04517955</nct_id>
  </id_info>
  <brief_title>TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores</brief_title>
  <official_title>TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm, observational trial of Transcatheter Aortic Valve Implantation (TAVI) with the&#xD;
      Medtronic Evolut R and Evolut Pro The primary objective of this trial is to evaluate device&#xD;
      success of TAVI with the Evolut R and Evolut Pro systems in septuagenarians with risk factors&#xD;
      for adverse surgical outcomes not captured by the traditional risk scores and therefore of&#xD;
      intermediate surgical risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of transcatheter aortic&#xD;
      valve implantation (TAVI) in septuagenarians with severe, symptomatic Aortic Stenosis (AS)&#xD;
      and risk factors for adverse surgical outcomes not captured by the traditional risk scores&#xD;
      and therefore of intermediate surgical risk.&#xD;
&#xD;
      The primary objective of this trial is to evaluate device success of TAVI with the Evolut R&#xD;
      and Evolut Pro systems in septuagenarians with risk factors for adverse surgical outcomes not&#xD;
      captured by the traditional risk scores and therefore of intermediate surgical risk.&#xD;
&#xD;
      The secondary objective is to assess early safety (at 30 days) and clinical efficacy (after&#xD;
      30 days) of the TAVI procedure.&#xD;
&#xD;
      Exploratory objective: comparative health economics in septuagenarians with symptomatic&#xD;
      severe aortic stenosis and intermediate surgical risk treated with Transcatheter Aortic Valve&#xD;
      Implantation (TAVI) vs Surgical Aortic Valve Replacement (SAVR) (matched historic cohort)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Device success (VARC-2 criteria)</measure>
    <time_frame>30 days</time_frame>
    <description>Absence of procedural mortality&#xD;
Correct positioning of the prosthetic heart valve into the proper anatomical location&#xD;
Intended performance of the prosthetic heart valve (mean aortic valve gradient&lt;20mmHg or peak velocity &lt; 3m/s, and no moderate or severe prosthetic valve regurgitation) as assessed with 24h post implantation and pre-discharge echocardiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of All-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All stroke (disabling and non-disabling)</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Life-threatening bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Acute Kidney Injury-Stage 2 or 3 (including renal replacement therapy)</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Coronary artery obstruction requiring intervention</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Major vascular complication</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Valve-related dysfunction requiring repeat procedure (BAV, TAVI or SAVR)</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of New pacemaker implantation</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All-cause mortality</measure>
    <time_frame>after 30 days and up to 2 years</time_frame>
    <description>Clinical Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All stroke (disabling and non-disabling)</measure>
    <time_frame>after 30 days and up to 2 years</time_frame>
    <description>Clinical Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hospitalizations for valve-related symptoms or worsening congestive heart failure NYHA class III or IV</measure>
    <time_frame>after 30 days and up to 2 years</time_frame>
    <description>Clinical Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Valve related dysfunction</measure>
    <time_frame>after 30 days and up to 2 years</time_frame>
    <description>Mean aortic valve gradient &gt;=20mmHg, Effective orifice area (EOA)&lt;=0.9-1.1cm2, and/or Dimensionless Valve Index (DVI)&lt;0.35 m/s and/or moderate or severe prosthetic valve regurgitation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation (TAVI)</intervention_name>
    <description>Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro</description>
    <other_name>Transcatheter Aortic Valve Replacement (TAVR)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 75-79 years old who have symptomatic severe aortic stenosis at intermediate&#xD;
        surgical risk defined by a Society of Thoracic Surgeons (STS) mortality risk of &gt;=4% and&#xD;
        &lt;=8%, will be presented to the Heart Team for inclusion in the trial.&#xD;
&#xD;
        Patients will have risk factors not captured by traditional risk scores&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 75-79&#xD;
&#xD;
          2. Subject must have Society of Thoracic Surgeons (STS) score &gt;=4% and &lt;=8%&#xD;
&#xD;
          3. Subject must have at least one from the risk factors presented below:&#xD;
&#xD;
             i. Severely atherosclerotic or porcelain aorta ii. Internal Mammary Artery (IMA) or&#xD;
             other conduit(s) crossing midline and/or adherent to posterior table of sternum iii.&#xD;
             Pre-existing mechanical valve in any other position iv. Severe right ventricular&#xD;
             dysfunction v. Hostile chest (abnormal chest wall anatomy due to severe kyphoscoliosis&#xD;
             or other skeletal abnormalities, evidence of severe radiation damage, history of&#xD;
             multiple recurrent pleural effusions causing internal adhesions) vi. Severe liver&#xD;
             disease/cirrhosis vii. Frailty viii. Malignancy with life expectancy that exceeds 24&#xD;
             months ix. Renal replacement therapy with creatinine levels &gt;200mmol/L or 2.26 mg/dl&#xD;
&#xD;
          4. Heart team consisting of at least one interventional cardiologist and one cardiac&#xD;
             surgeon agree on indication and treatment proposal, based on their clinical judgment&#xD;
             (including anatomy assessment, risk factors, etc)&#xD;
&#xD;
          5. Critical aortic valve area defined as an initial aortic valve area of &lt;=1cm2 or aortic&#xD;
             valve index &lt;0.6cm2/m2&#xD;
&#xD;
          6. In presence of normal left ventricular function:&#xD;
&#xD;
               1. Mean gradient &gt;40mmHg OR Vmax&gt;4m/sec OR&#xD;
&#xD;
               2. In presence of low flow, low gradient severe AS, a dobutamine stress echo must be&#xD;
                  conducted that demonstrates presence of contractile reserve defined as follows&#xD;
                  &gt;=20% increase in stroke volume and mean gradient &gt;40mmHg&#xD;
&#xD;
          7. Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York&#xD;
             Heart Association (NYHA) Functional Class II or greater&#xD;
&#xD;
          8. The subject is suitable for direct TAVI not preceded by balloon valvuloplasty&#xD;
             according to the judgment of the treating physicians&#xD;
&#xD;
          9. The subject and the treating physician agree that the subject will return for all&#xD;
             required post procedure follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity or contraindication to aspirin, heparin, clopidogrel, coumadin,&#xD;
             nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated;&#xD;
&#xD;
          2. Blood dyscrasias as defined: leukopenia (WBC&lt;1000/mm3), thrombocytopenia (platelet&#xD;
             count &lt;50.000cells/mm3), history of bleeding diathesis or coagulopathy;&#xD;
&#xD;
          3. Ongoing sepsis, including active endocarditis&#xD;
&#xD;
          4. Any condition considered a contraindication to extracorporeal assistance;&#xD;
&#xD;
          5. Symptomatic carotid or vertebral artery disease or successful treatment of carotid&#xD;
             stenosis within six weeks prior treatment&#xD;
&#xD;
          6. Cardiogenic shock manifested by low cardiac output, vasopressor dependence or&#xD;
             mechanical hemodynamic support;&#xD;
&#xD;
          7. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack&#xD;
             (TIA)&#xD;
&#xD;
          8. Active gastrointestinal (GI) bleeding within the past 3 months&#xD;
&#xD;
          9. Subject refuses a blood transfusion;&#xD;
&#xD;
         10. Severe dementia (resulting in either inability to provide informed consent for the&#xD;
             trial/procedure, prevents independent lifestyle outside of a chronic care facility, or&#xD;
             will fundamentally complicate rehabilitation from the procedure or compliance with&#xD;
             follow-up visits);&#xD;
&#xD;
         11. Multivessel coronary artery disease with a Syntax score &gt;22&#xD;
&#xD;
         12. Estimated life expectancy of less than 24 months due to associated non-cardiac&#xD;
             comorbid conditions&#xD;
&#xD;
         13. Other medical, social, or psychological conditions that in the opinion of the&#xD;
             investigator precludes the subject from appropriate consentor adherence to the&#xD;
             protocol required follow-up exams;&#xD;
&#xD;
         14. Currently participating in an investigational drug or another device trial (excluding&#xD;
             registries)&#xD;
&#xD;
         15. Evidence of an acute myocardial infarction &lt;=30 days before the index procedure&#xD;
&#xD;
         16. Need for emergency surgery for any reason&#xD;
&#xD;
         17. Uncontrolled atrial fibrillation&#xD;
&#xD;
             Anatomical Exclusion Criteria:&#xD;
&#xD;
         18. Native aortic annulus size &lt;18mm or &gt;30mm per the baseline diagnostic imaging;&#xD;
&#xD;
         19. Mixed aortic valve disease [aortic stenosis and aortic regurgitation with predominant&#xD;
             aortic regurgitation (3-4+]&#xD;
&#xD;
         20. Severe mitral or severe tricuspid regurgitation&#xD;
&#xD;
         21. Severe mitral stenosis;&#xD;
&#xD;
         22. Hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
         23. Echocardiographic or Multislice Computed Tomography (MSCT) evidence of intracardiac&#xD;
             mass, thrombus or vegetation&#xD;
&#xD;
         24. Anatomy of the aortic root and ascending aorta not suitable for TAVI with Evolut R or&#xD;
             Evolut Pro system (aortic root angulation &gt;70 degrees for femoral and left subclavian&#xD;
             access or &gt;30 degrees for right subclavian access)&#xD;
&#xD;
         25. Congenital bicuspid or unicuspid valve verified by echocardiography Vascular Exclusion&#xD;
             Criteria&#xD;
&#xD;
         26. Transarterial access not able to accommodate an 16 French sheath&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Tousoulis, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Cardiology, University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dimitris Tousoulis, Prof</last_name>
    <phone>+302132088099</phone>
    <email>tousoulis@med.uoa.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Konstantinos Toutouzas, Prof</last_name>
    <phone>+302132088099</phone>
    <email>ktoutouz@med.uoa.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Department, Hippokration Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dimitris Syrseloudis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Department of Cardiology, National &amp; Kapodistrian University of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Toutouzas, Prof</last_name>
      <phone>+302132088099</phone>
      <email>ktoutouz@med.uoa.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onassis Cardiac Surgery Center</name>
      <address>
        <city>Athens</city>
        <zip>17674</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vassilios Voudris, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fragkiskos Parthenakis, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lampros Michalis, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Dimitris Tousoulis</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>TAVI</keyword>
  <keyword>Evolut R</keyword>
  <keyword>Evolut Pro</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

